Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata

Alopecia Areata Clinical Trial

— AA  

Official title:

Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04964349
• Other study ID #: Alazhar faculty of medicine
• Secondary ID: Ahmed KadahEman
• Status: Recruiting
• Phase: Early Phase 1
• Start date: April 21, 2021
• Est. completion date: November 20, 2021

Study information

• Verified date: July 2021
• Source: Al-Azhar University
• Contact: Ahmed pr Elshahid, MD
• Phone: 00201006262271
• Email: ahmedandro[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alopecia areata is believed to be an autoimmune disease. Treatment primarily relies on intralesional and topical corticosteroids. This study was conducted to evaluate Jessener Solutionas a potential therapeutic modality of Alopecia Areataversusintralesional steroid as regards the efficacy, safety, tolerability, and patients' satisfaction.

Description:

Background Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss.Treatment primarily relies on intralesional and topical corticosteroids.Up till now, there is nouniversally proven therapy that induces and maintains remission of Alopecia Areata in all patients.

Aims The Aim of Study is to evaluate the efficacyof Jessener solution versus intralesional steroid in treatment of Alopecia Areata.

Patients and Methods The study will include 40 patients diagnosed clinically and dermoscopically as Alopecia Areata with more than two patches of alopecia areata were included. Two treatment modalities with intralesional corticosteroid and topical Jessener Solutionas were performed in two randomly selected patches. Three sessions were done, 3 weeks apart and were followed-up for three months. Evaluation was done using Mac Donald Hull and Norris grading system , Serial photographs and dermoscopic , trichoscopic examination every month will be done and patient will be score.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: November 20, 2021
• Est. primary completion date: October 21, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years to 40 Years

Eligibility

Inclusion Criteria:

• 1.Alopecia Areatamultilocuolaris.2.Age from18-50years old. 3.Wash out period is two months. 4.Ophiasis pattern alopecia areata.

Exclusion Criteria:

• Age less than 12 yearsand more than 40years old. 2.Patient under treatment.3.Patients having another dermatological condition affecting thescalpas eczema.4.Patients with psychiatric disorders.5.Pregnant and lactating females.

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata

Intervention

Drug:
• Corticosteroids Acting Locally
topical application of jessener solution

Locations

Country	Name	City	State
Egypt	Alazhar faculty of meidicine	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effecacy of topical jessener solution in treatment of alopecia areata	Effecacy of topical jessener solution in treatment of alopecia areata	6 monthes